Rajeev et al. demonstrated that mavoglurant, which is a subtype-selective and noncompetitive antagonist of the mGluR5 binding site, combined with higher doses of L-dopa may be effective in treating patients with PD experiencing L-dopa-related motor fluctuations and dyskinesia (Kumar et al., 2016). The gene discussed is GRM5; the disease is Parkinson disease.